104
Participants
Start Date
July 31, 2024
Primary Completion Date
July 31, 2025
Study Completion Date
July 31, 2026
ATLG
5 mg/kg/day IV for 4 consecutive days (day-5 to -2 before transplantation). All transplant recipients will receive myeloablative conditioning or modified myoloablative conditioning and standard GVHD prophylaxis.
ATLG
7.5mg/kg/day IV for 4 consecutive days (day-5 to -2 before transplantation). All transplant recipients will receive myeloablative conditioning or modified myoloablative conditioning and standard GVHD prophylaxis.
Tai'an City Central Hospital, Taian
Fujian Medical University Union Hospital, Fuzhou
The Southwest Hospital of Amu, Chongqing
People's Liberation Army The General Hospital of Western Theater Command, Chengdu
The First Bethune Hospital of Jilin University, Jilin
Institute of Hematology & Blood Diseases Hospital, China
OTHER